


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



DAWNRAYS PHARMACEUTICAL (HOLDINGS) LIMITED

東瑞製藥(控股)有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2348)

VOLUNTARY ANNOUNCEMENT

UPDATE ON PRODUCT DEVELOPMENT

Dawnrays Pharmaceutical (Holdings) Limited (the “Company”, together with its subsidiaries, collectively referred to as the “Group”) is pleased to announce that the Group’s subsidiary, Fujian Dawnrays Pharmaceutical Co., Ltd., has obtained the approval for drug production and registration for Trazodone Hydrochloride Tablets 50mg and 100mg from the National Medical Products Administration of China, being under type 3 chemical drug and regarded as passing the consistency evaluation. This product is suitable for the treatment of depression and is suitable for patients with or without anxiety.

This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.

By Order of the Board

Dawnrays Pharmaceutical (Holdings) Limited

Li Kei Ling

Chairman

Hong Kong, 29 May 2026

As at the date of this announcement, the board of the Company comprises two executive directors, namely Ms. Li Kei Ling and Mr. Hung Yung Lai; two non-executive directors, namely Mr. Leung Hong Man and Mr. Hu Shuo; and three independent non-executive directors, namely Mr. Lo Tung Sing Tony, Mr. Ede, Ronald Hao Xi and Ms. Lam Ming Yee Joan.

**for identification purpose only*